

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Sternberg et al.

Application No. 10/530,254

Filed: April 4, 2005

Confirmation No. 5499

**FILED VIA EFS ON
JUNE 14, 2007**

For: METHODS AND FORMULATIONS
COMPRISING AGONISTS AND
ANTAGONISTS OF NUCLEAR
HORMONE RECEPTORS

Examiner: Gyan Chandra

Art Unit: 1646

Attorney Reference No. 4239-66912-02

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

**SUBMITTED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE**

Listed on the accompanying form PTO-1449 and attached herewith are several English-language and/or non-English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

Applicants point out that although the 2nd edition of the Leppla *et al.* reference is cited in the specification, the 3rd edition is provided. Applicants were not able to obtain a copy of the 2nd edition of the reference.

Applicants filed this Information Disclosure Statement (“IDS”) before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Gillian L. Bunker, Ph.D./
Gillian L. Bunker, Ph.D.
Registration No. 47,461

cc: Docketing